Article Text

Download PDFPDF

Prevalence of psoriasis and associated risk factors in China: protocol of a nationwide, population-based, cross-sectional study
  1. Jing Li1,
  2. Meiwen Yu1,
  3. Ya-wen Wang2,
  4. Jia-an Zhang1,
  5. Mei Ju1,
  6. Kun Chen1,
  7. Yu Jiang2,
  8. Min Li1,3,
  9. Xiang-Sheng Chen1
  1. 1 Institute of Dermatology, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China
  2. 2 School of Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  3. 3 Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
  1. Correspondence to Dr Min Li; limin{at}pumcderm.cams.cn

Abstract

Introduction Psoriasis is a chronic inflammatory skin disease which could lead to serious complications and increased risk of cardiovascular diseases. Psoriasis was recognised as a serious non-communicable disease with important public health impact by member states in the World Health Assembly resolution in 2014. However, data on psoriasis epidemiology are scarce worldwide, especially from low-income and middle-income countries. Only a few epidemiological studies on psoriasis have been conducted in parts of China, mostly without appropriate sampling design and data analysis.

Aim This study aims to obtain the prevalence of psoriasis in China and relevant risk factors through a nationwide, population-based study with adequate statistical design.

Methods and analysis This is a cross-sectional study to be conducted in 60 sites across China. A multistage, cluster random sampling design is used. Participants should have local household registration or be residing in the survey area for at least 6 months during the past year. The presence of psoriasis is ascertained independently by two certified dermatologists. If any discrepancies in the diagnosis occur, consensus will be met via discussion. All participants will be interviewed with a questionnaire to collect sociodemographic and disease information. The field survey will be implemented from October 2018 to June 2019. All statistical analyses will be conducted using survey procedures in SAS V.9.2 software to adjust for the complex sample design.

Ethics and dissemination The study has been reviewed and approved by the ethics committee of the Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College (Nanjing, China). A written informed consent will be obtained from all participants before the questionnaire survey. Findings of the study will be disseminated through publications in peer-reviewed journals.

  • psoriasis
  • dermatological epidemiology
  • epidemiology

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • JL and MY contributed equally.

  • Contributors ML and X-SC conceptualised the study and secured funding. ML, JL, MY, JZ, MJ and KC were involved in the design of the study. JL, YW and YJ formulated the sampling procedure and data analysis plan. JL and MY drafted the manuscript. All authors have approved the final version.

  • Funding This work is supported by CAMS Innovation Fund for Medical Sciences (2017-I2M-1-017).

  • Competing interests None declared.

  • Ethics approval The study protocol has been reviewed and approved by the ethics committee of the Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College (Nanjing, China).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Not required.